Actelion Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Actelion Ltd To Cut Costs, Jobs To Help Specialty Focus-Reuters
Reuters reported that Actelion Ltd said it planned to cut up to 135 jobs as part of cost-cutting to focus on research in pulmonary arterial hypertension, or PAH. The firm said it was minimising the number of potential redundancies through natural attrition, early retirements and similar measures.
Latest Developments for Actelion Ltd
- Actelion Ltd Receives US FDA Approval Of Opsumit For The Treatment Of Pulmonary Arterial Hypertension
- Actelion Ltd Closes Acquisition Of Privately-held Ceptaris Therapeutics
- Actelion Ltd Raises FY 2013 EPS Guidance; Updates FY 2014 EPS Guidance; Lowers FY 2015 EPS Guidance-DJ
- Actelion Ltd Issues FY 2013 EPS Guidance Above Analysts' Estimates; Comments On FY 2014 And FY 2015 EPS Guidance-Conference Call
- Share this
- Digg this